Jay D. Kranzler

Jay D. Kranzler (board member) discloses dealings in 2 companies, chiefly Cypress Bioscience Inc and Avenue Therapeutics, Inc. In total, 410 filings cover trades dated from 9 January 2006 to 5 November 2024.

In open-market terms, that means 2 purchases worth €1,122 on one side and 387 sales worth €4.0M on the other. No amount is published for 31 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 6 share grants and 13 option exercises. So far in 2024, the count stands at 2 purchases and 1 sale.

Most recently, on 7 November 2024, the filings show an open-market sale worth €126 in Avenue Therapeutics, Inc. The last purchase on record was published on 1 October 2024, which is 753 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.